Building on decades of experience in the pharmaceutical industry we have developed a portfolio of novel compounds with demonstrated activity against key targets for the sensation of pain. We are forming a new company, Anocis, to develop and build the value in these assets. We are passionate about developing the next generation of pain treatments focusing particularly on chronic neuropathic pain and dysfunctions of sensation.
Our team, working in partnership with the European Lead Factory have jointly invested over £1.2 million to generate a series of drug discovery programmes that have yielded potent small molecule compounds against two key pain sensation pathways. These compounds display excellent drug-like properties and are well placed to be developed in to clinical candidates and ultimately new medicines.
The team are currently seeking investors to help fund the development of this exciting and innovative product.